92 related articles for article (PubMed ID: 8758470)
21. Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats.
Silley P; Stephan B; Greife HA; Pridmore A
J Antimicrob Chemother; 2007 Nov; 60(5):999-1003. PubMed ID: 17872918
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
Nord CE
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
[TBL] [Abstract][Full Text] [Related]
24. In vitro activities of three of the newer quinolones against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
[TBL] [Abstract][Full Text] [Related]
25. Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria.
Genzel GH; Stubbings W; Stîngu CS; Labischinski H; Schaumann R
Int J Antimicrob Agents; 2014 Nov; 44(5):420-3. PubMed ID: 25264128
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of DU-6859a against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
[TBL] [Abstract][Full Text] [Related]
27. Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.
Kato N; Kato H; Tanaka-Bandoh K; Watanabe K; Ueno K
J Antimicrob Chemother; 1997 Nov; 40(5):631-7. PubMed ID: 9421310
[TBL] [Abstract][Full Text] [Related]
28. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.
Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 1995 Jul; 39(7):1636-42. PubMed ID: 7492122
[TBL] [Abstract][Full Text] [Related]
29. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
Goldstein EJ
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S377-81. PubMed ID: 8324151
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of Bay Y3118 against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357
[TBL] [Abstract][Full Text] [Related]
32. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.
Liebetrau A; Rodloff AC; Behra-Miellet J; Dubreuil L
Antimicrob Agents Chemother; 2003 Nov; 47(11):3667-71. PubMed ID: 14576144
[TBL] [Abstract][Full Text] [Related]
33. The effect of DU-6859a, a new potent fluoroquinolone, on fecal microflora in human volunteers.
Inagaki Y; Yamamoto N; Chida T; Okamura N; Tanaka M
Jpn J Antibiot; 1995 Mar; 48(3):368-79. PubMed ID: 7752450
[TBL] [Abstract][Full Text] [Related]
34. In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients.
Mikamo H; Sato Y; Hayasaki Y; Kawazoe K; Tamaya T
Chemotherapy; 1999; 45(3):154-7. PubMed ID: 10224336
[TBL] [Abstract][Full Text] [Related]
35. [In vitro activity of several cytostatic drugs against aerobic and anaerobic intestinal bacteria].
Vetere A; Giuliano M; Pantosti A; Panichi G
Boll Ist Sieroter Milan; 1984; 63(6):505-9. PubMed ID: 6534396
[TBL] [Abstract][Full Text] [Related]
36. Impact of Low and High Doses of Marbofloxacin on the Selection of Resistant Enterobacteriaceae in the Commensal Gut Flora of Young Cattle: Discussion of Data from 2 Study Populations.
Lhermie G; Dupouy V; El Garch F; Ravinet N; Toutain PL; Bousquet-Mélou A; Seegers H; Assié S
Foodborne Pathog Dis; 2017 Mar; 14(3):152-159. PubMed ID: 28072925
[TBL] [Abstract][Full Text] [Related]
37. In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria.
Fernandes PB; Shipkowitz N; Bower RR; Jarvis KP; Weisz J; Chu DT
J Antimicrob Chemother; 1986 Dec; 18(6):693-701. PubMed ID: 3818495
[TBL] [Abstract][Full Text] [Related]
38. In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.
MacGowan AP; Bowker KE; Wootton M; Holt HA; Reeves DS
Antimicrob Agents Chemother; 1998 Feb; 42(2):419-24. PubMed ID: 9527797
[TBL] [Abstract][Full Text] [Related]
39. Impact of the fluoroquinolones on gastrointestinal flora.
Korten V; Murray BE
Drugs; 1993; 45 Suppl 3():125-33. PubMed ID: 7689443
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of quinolone resistance in anaerobic bacteria.
Oh H; Edlund C
Clin Microbiol Infect; 2003 Jun; 9(6):512-7. PubMed ID: 12848726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
